On Nov 08, major Wall Street analysts update their ratings for $Moderna (MRNA.US)$, with price targets ranging from $55 to $111.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $70.
BofA Securities analyst Alec Stranahan maintains with a hold rating, and adjusts the target price from $110 to $90.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $125 to $111.
TD Cowen analyst Tyler Van Buren maintains with a hold rating, and adjusts the target price from $60 to $55.
Needham analyst Joseph Stringer maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:
Moderna's Q3 SpikeVax revenue exceeded expectations, and the company has maintained its previously issued guidance. Despite this, a cautious outlook has been presented for 2025, which could be influenced by the anticipated approval of two additional vaccines.
Moderna's recent performance, which exceeded expectations in COVID vaccine sales, was partly due to the earlier commencement of the vaccination season compared to the previous year. Nevertheless, the company has adjusted its projection for vaccination rates for the year from initially expecting them to be consistent with last year's to now anticipating a possible decline of up to 10%. It was also mentioned that while the revenue forecast for the year has been maintained, the company anticipates results to be towards the lower end of the previously stated range.
Here are the latest investment ratings and price targets for $Moderna (MRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月8日，多家華爾街大行更新了$Moderna (MRNA.US)$的評級，目標價介於55美元至111美元。
摩根士丹利分析師Terence Flynn維持持有評級，維持目標價70美元。
美銀證券分析師Alec Stranahan維持持有評級，並將目標價從110美元下調至90美元。
巴克萊銀行分析師Gena Wang維持買入評級，並將目標價從125美元下調至111美元。
TD Cowen分析師Tyler Van Buren維持持有評級，並將目標價從60美元下調至55美元。
Needham分析師Joseph Stringer維持持有評級。
此外，綜合報道，$Moderna (MRNA.US)$近期主要分析師觀點如下：
moderna的Q3 SpikeVax營業收入超出預期，並且公司已經維持之前發佈的指引。儘管如此，對2025年持謹慎態度的展望表明，可能會受到預期批准兩種額外疫苗的影響。
moderna近期的表現超出了COVID疫苗銷售的預期，部分原因是疫苗接種季節比去年提前。儘管如此，公司已調整了對該年度疫苗接種率的預測，從最初預期與去年持平到現在預期可能下降最多10%。同時提到，儘管對該年度的營業收入預測保持不變，公司預計結果會在之前規定範圍的較低端。
以下爲今日6位分析師對$Moderna (MRNA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
